Open-label inteRventional Clinical Trial to Assess Efficacy and Safety of the exteMporaneous combInation of Nebivolol and Ramipril in hypertenSIve pAtients

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 266 participants.

Also called NCT06104423

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 266 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06104423
  • EudraCT 2022-003060-25
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Hungary (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06104423. Non-randomized; no masking; primary purpose treatment. Start 2023-10-02 (actual); primary completion 2024-02-19 (actual). Results posted on 2025-04-24.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Open-label inteRventional Clinical Trial to Assess Efficacy and Safety of the exteMporaneous combInation of Nebivolol and Ramipril in hypertenSIve pAtients
Acronym
ARTEMISIA
Condition
Hypertension
Intervention (Drug)
Nebivolol 5 mg
Intervention (Drug)
Ramipril 2.5/5/10 mg
Lead sponsor
Menarini International Operations Luxembourg SA (class: industry)

Record details

Record id
cardio:ct-nct06104423
Content hash
772f848278fefc0c438543149f1970d567acc20eb37fb828736910ace682b601